Explore

Trendline Trendline
FDA Alignment and AI Integration Critical for Rare Disease Drug Development

FDA Alignment and AI Integration Critical for Rare Disease Drug Development

FDA Alignment and AI Integration Critical for Rare Disease Drug Development
Trendline Trendline
FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements

FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements

FDA Alignment and AI Integration Crucial for Rare Disease Treatment Advancements
Trendline Trendline
Contineum Therapeutics Grants Stock Options to New Employee Under Nasdaq Rule

Contineum Therapeutics Grants Stock Options to New Employee Under Nasdaq Rule

Contineum Therapeutics Grants Stock Options to New Employee Under Nasdaq Rule
Trendline Trendline
Atisama Therapeutics Advances RB042 in Phase 1 Trial, Appoints New Board Chair

Atisama Therapeutics Advances RB042 in Phase 1 Trial, Appoints New Board Chair

Atisama Therapeutics Advances RB042 in Phase 1 Trial, Appoints New Board Chair
Trendline Trendline
Atisama Therapeutics Advances RB042 in Phase 1 Trial and Appoints New Board Chair

Atisama Therapeutics Advances RB042 in Phase 1 Trial and Appoints New Board Chair

Atisama Therapeutics Advances RB042 in Phase 1 Trial and Appoints New Board Chair
Trendline Trendline
Biogen's Alzheimer's Drug Results Support Tau Theory, Boosting Denali's Prospects

Biogen's Alzheimer's Drug Results Support Tau Theory, Boosting Denali's Prospects

Biogen's Alzheimer's Drug Results Support Tau Theory, Boosting Denali's Prospects
Trendline Trendline
Kariya and NeuraLight Collaborate to Advance GLP-1 Therapies for Neurodegeneration

Kariya and NeuraLight Collaborate to Advance GLP-1 Therapies for Neurodegeneration

Kariya and NeuraLight Collaborate to Advance GLP-1 Therapies for Neurodegeneration
Trendline Trendline
CREATE Secures $122 Million to Advance CAR T Cancer and Autoimmune Therapies

CREATE Secures $122 Million to Advance CAR T Cancer and Autoimmune Therapies

CREATE Secures $122 Million to Advance CAR T Cancer and Autoimmune Therapies
Trendline Trendline
Biogen's Alzheimer's Results Support Tau Theory, Boosting Denali's Prospects

Biogen's Alzheimer's Results Support Tau Theory, Boosting Denali's Prospects

Biogen's Alzheimer's Results Support Tau Theory, Boosting Denali's Prospects
Trendline Trendline
NanoViricides Reports $1.99M Net Loss in Q3 FY2026 Amid Clinical Advancements

NanoViricides Reports $1.99M Net Loss in Q3 FY2026 Amid Clinical Advancements

NanoViricides Reports $1.99M Net Loss in Q3 FY2026 Amid Clinical Advancements
Trendline Trendline
Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements

Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements

Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements
Trendline Trendline
Biogen's Alzheimer's Drug Advances Tau Theory, Boosts Denali's Prospects

Biogen's Alzheimer's Drug Advances Tau Theory, Boosts Denali's Prospects

Biogen's Alzheimer's Drug Advances Tau Theory, Boosts Denali's Prospects